SeQuent Scientific Ltd
NSE:SEQUENT
Intrinsic Value
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. [ Read More ]
The intrinsic value of one
SEQUENT
stock under the Base Case scenario is
66.35
INR.
Compared to the current market price of 124.35 INR,
SeQuent Scientific Ltd
is
Overvalued by 47%.
SeQuent Scientific Ltd's market capitalization is 31B INR.
SEQUENT stock price is 124.35 INR.
SEQUENT stock (66.35 INR) is 47% less than its price (124.35 INR).
SEQUENT stock (24.55 INR) is 80% less than its price (124.35 INR). Open DCF Valuation
SEQUENT stock (108.16 INR) is 13% less than its price (124.35 INR). Open Relative Valuation
SEQUENT has upside potential of 7% compared to the average analyst price target.
Open Wall St Estimates
SEQUENT has positive Free Cash Flow for the last twelve months.
SEQUENT's Revenue has been growing by 1% per year for the last 3 years.
SEQUENT's Revenue has dropped by 4% over the past 12 months.
SEQUENT's short-term assets (8B INR) exceed its short-term liabilties (6B INR).
SEQUENT has negative Operating Income for the last twelve months.
SEQUENT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2%.
SEQUENT's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 11% to -2%.
SEQUENT has a very low three-year average ROIC (Return on Invested Capital): 4%. The company is not efficient at using invested capital to generate operating income.
SEQUENT has negative Net Income for the last twelve months.
SEQUENT's long-term assets (15B INR) exceed its long-term liabilties (9B INR).
SEQUENT's ROE (Return on Equity) has significantly decreased in the last 3 years from 13% to -19%.
SEQUENT has positive Net Debt. This means that the company has more debt (2B INR) than cash and short-term investments (618m INR).
SEQUENT has negative three-year average ROE (Return on Equity): -1%. The company is not efficient at transforming stockholders' equity into net income.
SEQUENT has positive Gross Profit for the last twelve months.
SEQUENT's ROE (Return on Equity) for the past 12 months is negative and is equal to -19%.
SEQUENT's Altman Z-Score is very high and is equal to 3.45.
SEQUENT's D/E (Debt to Equity) is very low and is equal to 0.29.
SEQUENT doesn't generate enough operating income (-226m INR) to safely cover interest payments on its debt (421m INR).
Valuation Backtest
SeQuent Scientific Ltd
Run backtest to discover the historical profit from buying and selling
SEQUENT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
SeQuent Scientific Ltd
Balance Sheet Decomposition
SeQuent Scientific Ltd
| Current Assets | 7.7B |
| Cash & Short-Term Investments | 618.2m |
| Receivables | 3.1B |
| Other Current Assets | 4B |
| Non-Current Assets | 7.3B |
| Long-Term Investments | 130.5m |
| PP&E | 3.4B |
| Intangibles | 2.9B |
| Other Non-Current Assets | 872m |
| Current Liabilities | 6B |
| Accounts Payable | 2.8B |
| Other Current Liabilities | 3.3B |
| Non-Current Liabilities | 2.7B |
| Long-Term Debt | 1.9B |
| Other Non-Current Liabilities | 816.8m |
Earnings Waterfall
SeQuent Scientific Ltd
|
Revenue
|
13.8B
INR
|
|
Cost of Revenue
|
-7.9B
INR
|
|
Gross Profit
|
5.9B
INR
|
|
Operating Expenses
|
-6.1B
INR
|
|
Operating Income
|
-225.6m
INR
|
|
Other Expenses
|
-1.1B
INR
|
|
Net Income
|
-1.3B
INR
|
Free Cash Flow Analysis
SeQuent Scientific Ltd
SEQUENT Profitability Score
Profitability Due Diligence
SeQuent Scientific Ltd's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
SeQuent Scientific Ltd's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
SEQUENT Solvency Score
Solvency Due Diligence
SeQuent Scientific Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
SeQuent Scientific Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SEQUENT Price Targets Summary
SeQuent Scientific Ltd
According to Wall Street analysts, the average 1-year price target for
SEQUENT
is 133.5 INR
.
Shareholder Return
SEQUENT Price
SeQuent Scientific Ltd
| Average Annual Return | 22.38% |
| Standard Deviation of Annual Returns | 80.87% |
| Max Drawdown | -81% |
| Market Capitalization | 31B INR |
| Shares Outstanding | 248 471 245 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
SeQuent Scientific Ltd
Country
Industry
Market Cap
Dividend Yield
Description
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
Contact
IPO
Employees
Officers
The intrinsic value of one
SEQUENT
stock under the Base Case scenario is
66.35
INR.
Compared to the current market price of 124.35 INR,
SeQuent Scientific Ltd
is
Overvalued by 47%.
You don't have any saved screeners yet
